1. Omnipaque does not interfere with ADAMTS13 activity testing.
2. Diagnostic blood draws for suspected thrombotic thrombocytopenic purpura (TTP) cases need not be delayed after contrast administration.
3. The study focused on Omnipaque's interference with a specific fluorescence-based assay.
4. Findings suggest timely testing of ADAMTS13 activity following contrast administration for suspected TTP cases is supported.
5. The research did not evaluate alternative contrast media

Source: American Journal of Clinical Pathology